Published in Clin Cancer Res on July 19, 2013
Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood (2014) 2.84
Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol Res (2014) 2.25
Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov (2015) 2.25
The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol (2016) 2.09
Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment. J Immunother Cancer (2014) 1.92
Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med (2014) 1.59
Engineered T cells: the promise and challenges of cancer immunotherapy. Nat Rev Cancer (2016) 1.51
Generation of knock-in primary human T cells using Cas9 ribonucleoproteins. Proc Natl Acad Sci U S A (2015) 1.49
Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors. Cancer Discov (2015) 1.18
Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J Clin Invest (2016) 1.18
Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy. J Natl Cancer Inst (2016) 1.11
The pharmacology of second-generation chimeric antigen receptors. Nat Rev Drug Discov (2015) 1.09
Novel immunotherapies in lymphoid malignancies. Nat Rev Clin Oncol (2015) 1.09
Driving CAR T-cells forward. Nat Rev Clin Oncol (2016) 1.09
Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma. Leukemia (2013) 1.08
Acquired resistance to immunotherapy and future challenges. Nat Rev Cancer (2016) 1.08
Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. Oncoimmunology (2015) 1.06
Prospects for gene-engineered T cell immunotherapy for solid cancers. Nat Med (2016) 1.03
Clinical application of genetically modified T cells in cancer therapy. Clin Transl Immunology (2014) 1.03
Genetic modification of T cells redirected toward CS1 enhances eradication of myeloma cells. Clin Cancer Res (2014) 1.03
Blockade of PD-1 immunosuppression boosts CAR T-cell therapy. Oncoimmunology (2013) 1.01
Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs. Blood (2015) 1.00
Engineered T cells for cancer therapy. Cancer Immunol Immunother (2014) 0.95
CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients. Sci Rep (2016) 0.93
Immunotherapy for chronic lymphocytic leukemia in the era of BTK inhibitors. Leukemia (2013) 0.92
Impact of a New Fusion Receptor on PD-1-Mediated Immunosuppression in Adoptive T Cell Therapy. J Natl Cancer Inst (2015) 0.92
Blockade of Programmed Death 1 Augments the Ability of Human T Cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive Transfer. Clin Cancer Res (2015) 0.92
Relevance of tumor-infiltrating lymphocytes in breast cancer. BMC Med (2015) 0.92
Liver myeloid-derived suppressor cells expand in response to liver metastases in mice and inhibit the anti-tumor efficacy of anti-CEA CAR-T. Cancer Immunol Immunother (2015) 0.90
CD28z CARs and armored CARs. Cancer J (2014) 0.89
Smart CARs engineered for cancer immunotherapy. Curr Opin Oncol (2015) 0.88
Patient-derived glioblastoma stem cells are killed by CD133-specific CAR T cells but induce the T cell aging marker CD57. Oncotarget (2015) 0.88
Chimeric antigen receptor-engineered T cells for the treatment of metastatic prostate cancer. BioDrugs (2015) 0.86
Chimeric antigen receptor T-cell therapy for solid tumors. Mol Ther Oncolytics (2016) 0.86
Strategies and developments of immunotherapies in osteosarcoma. Oncol Lett (2015) 0.86
Current advances in T-cell-based cancer immunotherapy. Immunotherapy (2014) 0.86
Genetically modified T cells in cancer therapy: opportunities and challenges. Dis Model Mech (2015) 0.85
The Principles of Engineering Immune Cells to Treat Cancer. Cell (2017) 0.85
Novel immune checkpoint blocker approved for the treatment of advanced melanoma. Oncoimmunology (2014) 0.84
Chimeric antigen receptor-modified T cells for the treatment of solid tumors: Defining the challenges and next steps. Pharmacol Ther (2016) 0.82
Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition. Clin Cancer Res (2016) 0.82
Different Subsets of T Cells, Memory, Effector Functions, and CAR-T Immunotherapy. Cancers (Basel) (2016) 0.82
Adoptive T-Cell Immunotherapy. Curr Top Microbiol Immunol (2015) 0.81
CAR T Cell Therapy: A Game Changer in Cancer Treatment. J Immunol Res (2016) 0.81
Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection. Curr Opin Immunol (2016) 0.81
GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected From Activation-induced Cell Death by PD-1 Blockade. Mol Ther (2016) 0.81
Metabolic communication in tumors: a new layer of immunoregulation for immune evasion. J Immunother Cancer (2016) 0.81
Chimeric antigen receptor for adoptive immunotherapy of cancer: latest research and future prospects. Mol Cancer (2014) 0.80
CAR therapy for hematological cancers: can success seen in the treatment of B-cell acute lymphoblastic leukemia be applied to other hematological malignancies? Immunotherapy (2015) 0.80
Regional CAR-T cell infusions for peritoneal carcinomatosis are superior to systemic delivery. Cancer Gene Ther (2016) 0.80
Adoptive immunotherapy against ovarian cancer. J Ovarian Res (2016) 0.79
Better performance of CARs deprived of the PD-1 brake. Clin Cancer Res (2013) 0.79
Blockade of PD-1/PD-L1 promotes adoptive T-cell immunotherapy in a tolerogenic environment. PLoS One (2015) 0.79
Cellular immunotherapy for malignant gliomas. Expert Opin Biol Ther (2016) 0.79
Embryonic Lethality in Homozygous Human Her-2 Transgenic Mice Due to Disruption of the Pds5b Gene. PLoS One (2015) 0.79
Crystal clear: visualizing the intervention mechanism of the PD-1/PD-L1 interaction by two cancer therapeutic monoclonal antibodies. Protein Cell (2016) 0.78
CAR T-cell therapy of solid tumors. Immunol Cell Biol (2016) 0.78
Improving Adoptive T Cell Therapy: The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer Vaccination. Front Immunol (2016) 0.78
Identification and selective expansion of functionally superior T cells expressing chimeric antigen receptors. J Transl Med (2015) 0.78
Rapid and efficient transfer of the T cell aging marker CD57 from glioblastoma stem cells to CAR T cells. Oncoscience (2015) 0.78
Adoptive cell therapy for sarcoma. Immunotherapy (2015) 0.78
Focus on Nivolumab in NSCLC. Front Med (Lausanne) (2016) 0.78
Enhancing adoptive cancer immunotherapy with Vγ2Vδ2 T cells through pulse zoledronate stimulation. J Immunother Cancer (2017) 0.77
Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy. Front Oncol (2016) 0.77
Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model. Oncotarget (2016) 0.77
T cells targeting NY-ESO-1 demonstrate efficacy against disseminated neuroblastoma. Oncoimmunology (2015) 0.77
Genetically modified T-cell therapy for osteosarcoma. Adv Exp Med Biol (2014) 0.77
Therapeutic T cell engineering. Nature (2017) 0.77
Immune Therapy for Prostate Cancer. Cancer J (2016) 0.76
Targeting Ewing sarcoma with activated and GD2-specific chimeric antigen receptor-engineered human NK cells induces upregulation of immune-inhibitory HLA-G. Oncoimmunology (2016) 0.76
Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy. J Clin Invest (2017) 0.76
Reduction of MDSCs with All-trans Retinoic Acid Improves CAR Therapy Efficacy for Sarcomas. Cancer Immunol Res (2016) 0.76
Expression of a Chimeric Antigen Receptor in Multiple Leukocyte Lineages in Transgenic Mice. PLoS One (2015) 0.76
Homing to solid cancers: a vascular checkpoint in adoptive cell therapy using CAR T-cells. Biochem Soc Trans (2016) 0.76
Current approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironment. J Immunother Cancer (2017) 0.75
A role for multiple chimeric antigen receptor-expressing leukocytes in antigen-specific responses to cancer. Oncotarget (2016) 0.75
Chimeric Antigen Receptor T-Cell Therapy for the Community Oncologist. Oncologist (2016) 0.75
Potential Applications of Nanoparticles in Cancer Immunotherapy. Hum Vaccin Immunother (2016) 0.75
T cell therapy targeting a public neoantigen in microsatellite instable colon cancer reduces in vivo tumor growth. Oncoimmunology (2017) 0.75
Anti-GPC3-CAR T Cells Suppress the Growth of Tumor Cells in Patient-Derived Xenografts of Hepatocellular Carcinoma. Front Immunol (2017) 0.75
Metabolic regulation of immune responses: therapeutic opportunities. J Clin Invest (2016) 0.75
Molecular Pathways: Breaking the Epithelial Cancer Barrier for Chimeric Antigen Receptor and T-cell Receptor Gene Therapy. Clin Cancer Res (2016) 0.75
CARs: Synthetic Immunoreceptors for Cancer Therapy and Beyond. Trends Mol Med (2017) 0.75
Enhancement of PSMA-Directed CAR Adoptive Immunotherapy by PD-1/PD-L1 Blockade. Mol Ther Oncolytics (2016) 0.75
Structure-guided development of a high-affinity human Programmed Cell Death-1: Implications for tumor immunotherapy. EBioMedicine (2017) 0.75
Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatment. Oncotarget (2016) 0.75
Driving an improved CAR for cancer immunotherapy. J Clin Invest (2016) 0.75
Targeting immune checkpoints in malignant glioma. Oncotarget (2016) 0.75
PD-1 Blockade Modulates Chimeric Antigen Receptor (CAR) Modified T Cells and Induces Tumor Regression: Refueling the CAR. Blood (2016) 0.75
Antigen-specific T cells fully conserve antitumour function following cryopreservation. Immunol Cell Biol (2016) 0.75
Chimeric Antigen Receptor (CAR) T Cell Therapy for Malignant Pleural Mesothelioma (MPM). Cancers (Basel) (2017) 0.75
Development of CAR T cells designed to improve antitumor efficacy and safety. Pharmacol Ther (2017) 0.75
Driving better and safer HER2-specific CARs for cancer therapy. Oncotarget (2017) 0.75
In Vivo Murine-Matured Human CD3(+) Cells as a Preclinical Model for T Cell-Based Immunotherapies. Mol Ther Methods Clin Dev (2017) 0.75
Chemotherapy for Hepatocellular Carcinoma: Current Evidence and Future Perspectives. J Clin Transl Hepatol (2017) 0.75
Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science (2011) 15.79
Adaptive immunity maintains occult cancer in an equilibrium state. Nature (2007) 8.14
NKT cells: what's in a name? Nat Rev Immunol (2004) 7.84
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature (2012) 7.76
Natural innate and adaptive immunity to cancer. Annu Rev Immunol (2011) 7.09
Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med (2009) 6.73
Immune surveillance of tumors. J Clin Invest (2007) 5.04
IL-21 acts directly on B cells to regulate Bcl-6 expression and germinal center responses. J Exp Med (2010) 4.65
CD27 dissects mature NK cells into two subsets with distinct responsiveness and migratory capacity. J Immunol (2006) 4.48
The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer (2008) 4.42
An immunosurveillance mechanism controls cancer cell ploidy. Science (2012) 4.35
IL-21 regulates germinal center B cell differentiation and proliferation through a B cell-intrinsic mechanism. J Exp Med (2010) 4.04
Functional significance of the perforin/granzyme cell death pathway. Nat Rev Immunol (2002) 3.96
Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity (2013) 3.73
Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity (2013) 3.26
The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy. Blood (2010) 3.23
Functional interactions between dendritic cells and NK cells during viral infection. Nat Immunol (2002) 3.20
Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis. Proc Natl Acad Sci U S A (2008) 3.19
A natural killer T (NKT) cell developmental pathway iInvolving a thymus-dependent NK1.1(-)CD4(+) CD1d-dependent precursor stage. J Exp Med (2002) 3.13
Perforin-mediated target-cell death and immune homeostasis. Nat Rev Immunol (2006) 3.04
IL-21 is produced by NKT cells and modulates NKT cell activation and cytokine production. J Immunol (2007) 2.99
A network of PDZ-containing proteins regulates T cell polarity and morphology during migration and immunological synapse formation. Immunity (2005) 2.97
Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J Immunol (2002) 2.88
Differential antitumor immunity mediated by NKT cell subsets in vivo. J Exp Med (2005) 2.83
Close encounters of different kinds: dendritic cells and NK cells take centre stage. Nat Rev Immunol (2005) 2.77
A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas. J Exp Med (2002) 2.73
BAFF and MyD88 signals promote a lupuslike disease independent of T cells. J Exp Med (2007) 2.70
Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis. Proc Natl Acad Sci U S A (2010) 2.67
Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nat Med (2012) 2.66
Differential recognition of CD1d-alpha-galactosyl ceramide by the V beta 8.2 and V beta 7 semi-invariant NKT T cell receptors. Immunity (2009) 2.61
Anti-TIM3 antibody promotes T cell IFN-γ-mediated antitumor immunity and suppresses established tumors. Cancer Res (2011) 2.59
Diverse cytokine production by NKT cell subsets and identification of an IL-17-producing CD4-NK1.1- NKT cell population. Proc Natl Acad Sci U S A (2008) 2.57
Membrane-bound Fas ligand only is essential for Fas-induced apoptosis. Nature (2009) 2.54
Glycolipid antigen drives rapid expansion and sustained cytokine production by NK T cells. J Immunol (2003) 2.48
Differential development of murine dendritic cells by GM-CSF versus Flt3 ligand has implications for inflammation and trafficking. J Immunol (2007) 2.43
Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc Natl Acad Sci U S A (2011) 2.35
A nonclassical non-Valpha14Jalpha18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance. J Exp Med (2005) 2.32
Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. J Clin Invest (2013) 2.30
NK cell maturation and peripheral homeostasis is associated with KLRG1 up-regulation. J Immunol (2007) 2.26
Presumed guilty: natural killer T cell defects and human disease. Nat Rev Immunol (2011) 2.21
Cutting edge: IL-21 is not essential for Th17 differentiation or experimental autoimmune encephalomyelitis. J Immunol (2008) 2.19
Eradication of established tumors in mice by a combination antibody-based therapy. Nat Med (2006) 2.10
Cytokines in cancer immunity and immunotherapy. Immunol Rev (2004) 2.09
Supernatural T cells: genetic modification of T cells for cancer therapy. Nat Rev Immunol (2005) 2.08
Gene-engineered T cells for cancer therapy. Nat Rev Cancer (2013) 2.07
Innate immunity defines the capacity of antiviral T cells to limit persistent infection. J Exp Med (2010) 2.06
Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy. J Exp Med (2011) 2.04
CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis. Cancer Res (2011) 2.03
IL-21 induces the functional maturation of murine NK cells. J Immunol (2004) 2.00
DNAM-1 promotes activation of cytotoxic lymphocytes by nonprofessional antigen-presenting cells and tumors. J Exp Med (2008) 2.00
Interleukin 15-mediated survival of natural killer cells is determined by interactions among Bim, Noxa and Mcl-1. Nat Immunol (2007) 1.97
Functional subsets of mouse natural killer cells. Immunol Rev (2006) 1.95
Chemotherapy and radiotherapy: cryptic anticancer vaccines. Semin Immunol (2010) 1.94
Cancer immunoediting by the innate immune system in the absence of adaptive immunity. J Exp Med (2012) 1.93
Type I natural killer T cells suppress tumors caused by p53 loss in mice. Blood (2009) 1.91
Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J Exp Med (2002) 1.88
Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors. Cancer Res (2011) 1.88
Suppression of lymphoma and epithelial malignancies effected by interferon gamma. J Exp Med (2002) 1.85
Type I IFN contributes to NK cell homeostasis, activation, and antitumor function. J Immunol (2007) 1.84
Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors. Blood (2002) 1.83
TRAIL identifies immature natural killer cells in newborn mice and adult mouse liver. Blood (2004) 1.83
Tumor cell death and ATP release prime dendritic cells and efficient anticancer immunity. Cancer Res (2010) 1.82
The pre-metastatic niche: finding common ground. Cancer Metastasis Rev (2013) 1.82
Immune-mediated dormancy: an equilibrium with cancer. J Leukoc Biol (2008) 1.75
Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy. J Exp Med (2004) 1.73
Fatal hepatitis mediated by tumor necrosis factor TNFalpha requires caspase-8 and involves the BH3-only proteins Bid and Bim. Immunity (2009) 1.73
Conditional regulatory T-cell depletion releases adaptive immunity preventing carcinogenesis and suppressing established tumor growth. Cancer Res (2010) 1.71
Induction of tumor-specific T cell memory by NK cell-mediated tumor rejection. Nat Immunol (2001) 1.70
The influence of CD1d in postselection NKT cell maturation and homeostasis. J Immunol (2005) 1.68
Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma. Cancer Res (2010) 1.66
A potential role for RAG-1 in NK cell development revealed by analysis of NK cells during ontogeny. Immunol Cell Biol (2009) 1.63
Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies. Cancer Res (2012) 1.59
Activating and inhibitory receptors of natural killer cells. Immunol Cell Biol (2010) 1.58
A structural basis for selection and cross-species reactivity of the semi-invariant NKT cell receptor in CD1d/glycolipid recognition. J Exp Med (2006) 1.56
CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer. Proc Natl Acad Sci U S A (2013) 1.54
TRAIL and its receptors as targets for cancer therapy. Cancer Sci (2004) 1.53
Long-term retention of mature NK1.1+ NKT cells in the thymus. J Immunol (2006) 1.53
CD73: a potent suppressor of antitumor immune responses. Trends Immunol (2012) 1.52
Plasma cell S1P1 expression determines secondary lymphoid organ retention versus bone marrow tropism. J Exp Med (2006) 1.51
Cutting edge: tumor rejection mediated by NKG2D receptor-ligand interaction is dependent upon perforin. J Immunol (2002) 1.50